215 related articles for article (PubMed ID: 21681495)
1. Localization of sporadic neuroendocrine tumors by gene expression analysis of their metastases.
Posorski N; Kaemmerer D; Ernst G; Grabowski P; Hoersch D; Hommann M; von Eggeling F
Clin Exp Metastasis; 2011 Oct; 28(7):637-47. PubMed ID: 21681495
[TBL] [Abstract][Full Text] [Related]
2. Benefit of Gene Expression Profiling in Gastrointestinal Neuroendocrine Tumors of Unknown Primary Origin.
Saller JJ; Haider M; Al-Diffalha S; Coppola D
Anticancer Res; 2022 Mar; 42(3):1381-1396. PubMed ID: 35220231
[TBL] [Abstract][Full Text] [Related]
3. The search for the primary tumor in metastasized gastroenteropancreatic neuroendocrine neoplasm.
Kaemmerer D; Posorski N; von Eggeling F; Ernst G; Hörsch D; Baum RP; Prasad V; Langer R; Esposito I; Klöppel G; Sehner S; Knösel T; Hommann M
Clin Exp Metastasis; 2014 Oct; 31(7):817-27. PubMed ID: 25098566
[TBL] [Abstract][Full Text] [Related]
4. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Cigrovski Berković M; Čačev T; Catela Ivković T; Marout J; Ulamec M; Zjačić-Rotkvić V; Kapitanović S
Mol Cell Endocrinol; 2016 Apr; 425():61-8. PubMed ID: 26805636
[TBL] [Abstract][Full Text] [Related]
5. Genes involved in neuroendocrine tumor biology.
Hofsli E
Pituitary; 2006; 9(3):165-78. PubMed ID: 17001466
[TBL] [Abstract][Full Text] [Related]
6. A 92-gene cancer classifier predicts the site of origin for neuroendocrine tumors.
Kerr SE; Schnabel CA; Sullivan PS; Zhang Y; Huang VJ; Erlander MG; Brachtel EF; Dry SM
Mod Pathol; 2014 Jan; 27(1):44-54. PubMed ID: 23846576
[TBL] [Abstract][Full Text] [Related]
7. Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumors through DNA microarray analysis.
Duerr EM; Mizukami Y; Ng A; Xavier RJ; Kikuchi H; Deshpande V; Warshaw AL; Glickman J; Kulke MH; Chung DC
Endocr Relat Cancer; 2008 Mar; 15(1):243-56. PubMed ID: 18310291
[TBL] [Abstract][Full Text] [Related]
8. Tumor suppressor genes in the 9p21 gene cluster are selective targets of inactivation in neuroendocrine gastroenteropancreatic tumors.
Lubomierski N; Kersting M; Bert T; Muench K; Wulbrand U; Schuermann M; Bartsch D; Simon B
Cancer Res; 2001 Aug; 61(15):5905-10. PubMed ID: 11479232
[TBL] [Abstract][Full Text] [Related]
9. Meta-iodobenzylguanidine induces growth inhibition and apoptosis of neuroendocrine gastrointestinal tumor cells.
Höpfner M; Sutter AP; Beck NI; Barthel B; Maaser K; Jockers-Scherübl MC; Zeitz M; Scherübl H
Int J Cancer; 2002 Sep; 101(3):210-6. PubMed ID: 12209970
[TBL] [Abstract][Full Text] [Related]
10. Angiopoietin-2 promotes disease progression of neuroendocrine tumors.
Detjen KM; Rieke S; Deters A; Schulz P; Rexin A; Vollmer S; Hauff P; Wiedenmann B; Pavel M; Scholz A
Clin Cancer Res; 2010 Jan; 16(2):420-9. PubMed ID: 20068079
[TBL] [Abstract][Full Text] [Related]
11. A practical method to determine the site of unknown primary in metastatic neuroendocrine tumors.
Maxwell JE; Sherman SK; Stashek KM; O'Dorisio TM; Bellizzi AM; Howe JR
Surgery; 2014 Dec; 156(6):1359-65; discussion 1365-6. PubMed ID: 25456909
[TBL] [Abstract][Full Text] [Related]
12. Integrating a 92-Gene Expression Analysis for the Management of Neuroendocrine Tumors of Unknown Primary.
Chauhan A; Farooqui Z; Silva SR; Murray A; Hodges KB; Yu Q; Myint ZW; Raajesekar AK; Weiss H; Arnold S; Evers BM; Anthony L
Asian Pac J Cancer Prev; 2019 Jan; 20(1):113-116. PubMed ID: 30678389
[TBL] [Abstract][Full Text] [Related]
13. Analysis of molecular pathways in neuroendocrine cancers of the gastroenteropancreatic system.
Arnold CN; Sosnowski A; Blum HE
Ann N Y Acad Sci; 2004 Apr; 1014():218-9. PubMed ID: 15153437
[TBL] [Abstract][Full Text] [Related]
14. Clinico-morphological analysis of the neuroendocrine neoplasms of the gastroenteropancreatic system.
Delektorskaya VV; Kozlov NA; Chemeris GY
Klin Lab Diagn; 2013 Oct; (10):48-50, 10-3. PubMed ID: 24640093
[TBL] [Abstract][Full Text] [Related]
15. Tumour biology and histopathology of neuroendocrine tumours.
Klöppel G
Best Pract Res Clin Endocrinol Metab; 2007 Mar; 21(1):15-31. PubMed ID: 17382263
[TBL] [Abstract][Full Text] [Related]
16. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE).
Garcia-Carbonero R; Capdevila J; Crespo-Herrero G; Díaz-Pérez JA; Martínez Del Prado MP; Alonso Orduña V; Sevilla-García I; Villabona-Artero C; Beguiristain-Gómez A; Llanos-Muñoz M; Marazuela M; Alvarez-Escola C; Castellano D; Vilar E; Jiménez-Fonseca P; Teulé A; Sastre-Valera J; Benavent-Viñuelas M; Monleon A; Salazar R
Ann Oncol; 2010 Sep; 21(9):1794-1803. PubMed ID: 20139156
[TBL] [Abstract][Full Text] [Related]
17. Molecular genetics of gastroenteropancreatic neuroendocrine tumors.
Starker LF; Carling T
Curr Opin Oncol; 2009 Jan; 21(1):29-33. PubMed ID: 19125015
[TBL] [Abstract][Full Text] [Related]
18. [Current trend: endocrine tumors of the stomach, small bowel, colon and rectum].
O'Toole D
Gastroenterol Clin Biol; 2006 Feb; 30(2):276-91. PubMed ID: 16565662
[No Abstract] [Full Text] [Related]
19. PCSK2 expression in neuroendocrine tumors points to a midgut, pulmonary, or pheochromocytoma-paraganglioma origin.
Remes SM; Leijon H; Vesterinen T; Louhimo J; Pulkkinen V; Ezer S; Kere J; Haglund C; Arola J
APMIS; 2020 Nov; 128(11):563-572. PubMed ID: 32794589
[TBL] [Abstract][Full Text] [Related]
20. Molecular genetics of gastroenteropancreatic neuroendocrine tumors.
Toumpanakis CG; Caplin ME
Am J Gastroenterol; 2008 Mar; 103(3):729-32. PubMed ID: 18341492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
